

**APPLICATION**

**FOR**

**UNITED STATES LETTERS PATENT**

**BY**

**JACK L. ARBISER**

**FOR**

**CURCUMIN AND CURCUMINOID INHIBITION OF ANGIOGENESIS**

# CURCUMIN AND CURCUMINOID INHIBITION OF ANGIOGENESIS

*Ensal*

## Background of the Invention

The invention is generally in the field of methods of inhibiting  
5 angiogenesis, and more specifically is drawn to methods and compositions for inhibiting angiogenesis.

The United States government has rights in this invention by virtue of grant R03 AR44947 from the National Institutes of Health.

Current treatments of cancer and related diseases have limited  
10 effectiveness and numerous serious unintended effects. Based primarily on chemical, radiation and surgical therapy, these treatments have progressed only incrementally during more than thirty years of intensive research to discover the origins and devise improved therapies of neoplastic diseases.

Current research strategies emphasize the search for effective therapeutic  
15 modes with less risk, including the use of natural products and biological agents. This change in emphasis has been stimulated by the fact that many of the consequences, to patients and their offspring, of conventional cancer treatment, including new cancers, mutations and congenital defects, result from their actions on genetic material and mechanisms. Hong et al., J. Natl. Cancer Inst.  
20 Monogr. 17:49-53 (1995). Efforts continue to discover the origins of cancer at the genetic level, and correspondingly new treatments, but such interventions also may have serious unanticipated effects.

The observation by Folkman that tumors are highly vascular, and the elucidation by him and others of a process termed *angiogenesis* through which  
25 many tumors derive a blood supply by the generation of microvessels, provided an important new avenue to therapy of cancer and other diseases and disorders. Folkman, Proc. Natl. Acad. Sci. U. S. A. 95(16):9064-6 (1998); C. R. Acad. Sci. III 316(9):909-918 (1993). Angiogenesis has now been recognized in inflammatory lesions and benign tumors, in addition to malignant tumors.

30 Mammals are characterized by complex cardiovascular systems that enable their warm-blooded nature, internal embryonic and fetal development and

successful population of extreme habitats. The development of an extensive capillary system, specialized in each organ and tissue, is an essential feature of mammalian cardiovascular systems, to provide optimal distribution of nutrients and other substances including hormones and defensive agents. The metabolic and physiologic needs of mammalian cells are met by their proximity to capillaries, and limited resources may be diverted by imbalance of this supply system. Tortora, "Principles of Human Anatomy", 5<sup>th</sup> ed., pp. 371-372, Harper & Row, N. Y. (1989).

Angiogenesis results primarily from the development of new or lengthened capillaries, and larger microvessels. Capillaries are formed primarily of specialized endothelial cells and the connective tissue layer to which they adhere, the basement membrane. The proliferation of endothelial cells and their migration and orientation to form capillaries is recognized as the key process regulated in the control of angiogenesis. Neovascularization is a form of angiogenesis marked by formation of blood vessels in a tissue or region previously devoid of blood vessel supply, for example the cornea of the eye. The mechanisms involved in angiogenesis are quite complicated, however, and no one appears to be the sole controlling mechanism.

Mammals have effective mechanisms to regulate this vital process. Stimulation of angiogenesis in adult mammals, other than as a part of normal tissue repair, pregnancy or the menstrual cycle, is abnormal and often pathological. Many malignant tumors, benign tumors and inflammatory lesions have the ability to evade or mobilize these regulatory mechanisms to support their growth and further malignant progression.

Development of effective preventive and treatment means has been hampered by inadequate understanding of the factors controlling this process. The premise of therapeutic development for such conditions is that effective treatment does not require destruction of the cells or tissues of origin. Reduction or prevention of the increased blood supply can be sufficient to prevent their

growth, and the manifestation of the condition as a disease or pathological disorder.

This concept was initially rejected, but widespread recognition of angiogenesis as a major factor in a variety of pathological conditions and diseases, particularly cancer and pre-cancerous conditions, has occurred recently among scientists and businesses. It is estimated that 184 million U. S. and European Union (EU) disease cases could benefit from treatment to inhibit angiogenesis that is inappropriate and pathological (anti-angiogenic therapy), in addition to an estimated 314 million disease cases in the U.S. and EU that might benefit from treatment to stimulate angiogenesis, for example in cardiac rehabilitation. Thirty-one specific projects of pharmaceutical and biotechnology companies to develop anti-angiogenic treatment were reported in Gen. Eng. News 18(17):1, 8, 34, 46 (1998).

It is an object of the present invention to provide methods of treating a mammal having a disease or condition characterized by increased angiogenesis.

It is a further object of the present invention to provide a method of preventing the initiation or progression of a disease or condition characterized by increased angiogenesis in a mammal, especially skin diseases and diseases characterized by elevated basic fibroblast growth factor.

### Summary of the Invention

Methods for treating diseases or disorders of the skin which are characterized by angiogenesis have been developed using curcumin and curcumin analogs. Based on the results obtained with curcumin, it has been determined that other angiogenesis inhibitors can also be used to treat these skin disorders. It was also discovered that curcumin acts to inhibit angiogenesis in part by inhibition of basic fibroblast growth factor (bFGF), and thereby provides a means for treating other disorders characterized by elevated levels of bFGF, such as bladder cancer, using curcumin and other analogues which also inhibit bFGF.

Curcumin and demethoxycurcumin are the preferred agents for treating these disorders. The preferred means of administration is to apply the curcumin topically, for example, as an ointment or hydrogel containing between one-half percent (0.5%) and five percent (5%) of the curcumin, or regionally, orally to  
5 treat disorders of the gastrointestinal tract or by instillation, to treat bladder or cervical cancer. In alternative embodiments, the curcumin or its analogs can be implanted in the form of one or more pellets of a pharmaceutically acceptable vehicle encapsulating or incorporating the curcumin, or by one or more injections of a pharmaceutically acceptable aqueous solution including the  
10 curcumin.

Representative skin disorders include the malignant diseases angiosarcoma, hemangioendothelioma, basal cell carcinoma, squamous cell carcinoma, malignant melanoma and Kaposi's sarcoma, and the non-malignant diseases or conditions including psoriasis, lymphangiogenesis, hemangioma of  
15 childhood, Sturge-Weber syndrome, verruca vulgaris, neurofibromatosis, tuberous sclerosis, pyogenic granulomas, recessive dystrophic epidermolysis bullosa, venous ulcers, acne, rosacea, eczema, molluscum contagious, seborrheic keratosis, and actinic keratosis. Representative disorders characterized by increased levels of bFGF include bladder and cervical cancers.

20 As demonstrated in the examples, curcumin and its analogs are potent inhibitors of endothelial cell proliferation, a sensitive test of *in vitro* antiangiogenic effectiveness, and also of corneal neovascularization, a sensitive and reliable test of *in vivo* antiangiogenic effectiveness. The examples demonstrate that this inhibition is exerted directly on the endothelial cells that  
25 are primarily involved in angiogenesis, and not indirectly through other effects of these agents. The examples further demonstrate that curcumin and its analogs inhibit the stimulation of angiogenesis *in vivo* by basic fibroblast growth factor.

### Brief Description of the Drawings

Figures 1A-C describe the effect of curcumin on endothelial cell  
30 proliferation in the absence of basic fibroblast growth factor (bFGF; Figure 1A),

in the presence of bFGF (Figure 1B) and in the absence of bFGF, where the endothelial cells have been transformed (Figure 1C). The figures are graphs of cell number versus concentration of curcumin ( $\mu\text{M}$ ).

Figures 2A-2B describe the effect of curcumin on the extent of bFGF-stimulated neovascularization in the mouse cornea (Figure 2A), in relation to bFGF-stimulated neovascularization in the absence of curcumin (Figure 2B). The figures are graphs of vessel length (mm) and sector size (clock hours) comparing curcumin (10  $\mu\text{M}$ ) with control TPCPD, with both in the presence of 80 ng bFGF.

Figures 3A and 3B describe the effect of curcumin and other curcuminoids, tetrahydrocurcumin, bisdemethoxycurcumin, and demethoxycurcumin, on corneal neovascularization, as measured by vessel length (Fig. 3A) and by sector size (Fig. 3B).

### Detailed Description of the Invention

#### I. Disorders to be Treated

Disorders or diseases that can be treated with the angiogenesis inhibitors include those characterized by elevated levels of basic fibroblast growth factor (bFGF), and a number of dermatological disorders.

Diseases and pathological disorders of the skin characterized by angiogenesis in humans include the malignant diseases angiosarcoma, hemangioendothelioma, basal cell carcinoma, squamous cell carcinoma, malignant melanoma and Kaposi's sarcoma, and the non-malignant diseases or conditions psoriasis, lymphangiogenesis, hemangioma of childhood, Sturge-Weber syndrome, verruca vulgaris, neurofibromatosis, tuberous sclerosis, pyogenic granulomas, recessive dystrophic epidermolysis bullosa, venous ulcers, acne, rosacea, eczema, molluscum contagiosus, seborrheic keratosis, and actinic keratosis.

Examples of disorders characterized by elevated levels of bFGF include bladder cancer (O'Brien, et al. Cancer Res. 57(1):136-140 (1997)) and cervical

cancer (which is caused by a herpes papilloma virus, known to elicit elevated levels of bFGF).

## II. Pharmaceutical Compositions

### A. Angiogenesis Inhibitors

5 Several different classes of compounds have been determined to be useful as inhibitors of angiogenesis. These include collagenase inhibitors such as metalloproteinases and tetracyclines such as minocycline, naturally occurring peptides such as endostatin and angiostatin, described for example in U.S. patent No. 5,733,876 to O'Reilly, et al., U.S. patent No. 5,290,807, and U.S. Patent No. 10 5,639,725, fungal and bacterial derivatives, such as fumagillin derivatives like TNP-470, the sulfated polysaccharides described in U.S. patent No. 4,900,815 to Tanaka, et al. and the protein-polysaccharides of U.S. patent No. 4,975,422 to Kanoh, et al. and synthetic compounds such as the 2,5-diaryltetrahydrofurans of U.S. patent No. 5,629,340 to Kuwano, et al., aminophenylphosphonic acid 15 compounds of U.S. patent No. 5,670,493 to Cordi, et al., the 3-substituted oxindole derivatives of U.S. patent No. 5,576,330 to Buzzetti, et al., and thalidomides of U.S. patent No. 5,712,291 to D'Amato.

The antibiotics that are useful as angiogenesis inhibitors are those having collagenase inhibitory activity. These include the tetracyclines and chemically 20 modified tetracyclines (CMTs), and three ringed tetracycline homologs, that have the ability to inhibit collagenase but diminished antibacterial activity. Examples of commercially available tetracyclines include chlortetracycline, demeclocycline, doxycycline, lymecycline, methacycline, minocycline, oxytetracycline, rolitetracycline, and tetracycline. The active salts, which are 25 formed through protonation of the dimethylamino group on carbon atom 4, exist as crystalline compounds. These are stabilized in aqueous solution by addition of acid.

Minocycline, a semisynthetic tetracycline antimicrobial, described by Martell, M. J., and Boothe, J. H. in J. Med. Chem., 10: 44-46 (1967), and 30 Zbinovsky, Y., and Chrikian, G. P. Minocycline. In: K. Florey (ed.), Analytical

Profiles of Drug Substances, pp. 323-339 (Academic Press, NY 1977), the teachings of which are incorporated herein, has anticollagenase properties, as reported by Golub, L. M., et al., , J. Periodontal Res., 18: 516-526 (1983); Golub, L. M., et al., J. Periodontal Res. 19: 651-655 (1984); Golub, L. M., et al., 5 J. Periodontal Res. 20: 12-23 (1985); and Golub, L. M., et al., J. Dent. Res., 66: 1310-1314 (1987). Minocycline, first described in 1967, is derived from the naturally produced parent compounds chlortetracycline and oxytetracycline. The chemically modified tetracyclines are described by U.S. Patent No. 4,704,383 to McNamara, et al., 4,925,833 to McNamara, et al., and 4,935,411 to 10 McNamara, et al., the teachings of which are incorporated herein.

Other exemplary anti-angiogenic compounds include penicillamine and some cytokines such as IL12.

Angiogenesis inhibitors may be divided into at least two classes. The first class, direct angiogenesis inhibitors, includes those agents which are 15 relatively specific for endothelial cells and have little effect on tumor cells. Examples of these include soluble vascular endothelial growth factor (VEGF) receptor antagonists and angiostatin. Basic fibroblast growth factor (bFGF) is a potent, direct angiogenic factor, which has been shown to be a strong stimulus for both endothelial proliferation and migration, *in vitro* and *in vivo*. The 20 activity of bFGF on endothelial cells may be due in part to stimulation of protein kinase C. Shing et al., Science 223:1296-1299 (1984); Kent et al., Circ. Res. 77:231-238 (1995). Blockage of bFGF's stimulation of endothelial cells can inhibit angiogenesis.

Indirect inhibitors may not have direct effects on endothelial cells but 25 may down-regulate the production of an angiogenesis stimulator, such as VEGF. Arbiser et al., Molec. Med. 4:376-383 (1998). VEGF has been shown to be up-regulated during chemically induced skin carcinogenesis; this is likely due to activation of oncogenes, such as H-ras. Arbiser et al., Proc. Natl. Acad. Sci. U. S. A. 94:861-866 (1997); Larcher et al., Cancer Res. 56:5391-5396 (1996); Kohl 30 et al., Nature Med. 1:792-797 (1995). Examples of indirect inhibitors of

angiogenesis include inhibitors of ras-mediated signal transduction, such as farnesyltransferase inhibitors.

Direct inhibition of endothelial cell proliferation can be assayed in cell culture systems, in which the effects of specific factors which control the  
5 complex process of angiogenesis can be studied. Effects discovered in such *in vitro* systems can then be studied in *in vivo* systems. Kenyon et al., Invest. Ophthalmol. 37:1625-1632 (1996).

Curcumin (diferuloylmethane) and certain of its analogs, together termed curcuminoids, are well known natural products, recognized as safe for ingestion  
10 by and administration to mammals including humans. Bille et al., Food Chem. Toxicol. 23:967-971 (1985). Curcumin is a yellow pigment found in the rhizome of *Curcuma longa*, the source of the spice turmeric. Turmeric has been a major component of the diet of the Indian subcontinent for several hundred years, and the average daily consumption of curcumin has been found to range  
15 up to 0.6 grams for some individuals, without reported adverse effects. Food-grade curcumin consists of the three curcuminoids in the relative amounts: 77% curcumin, 17% demethoxycurcumin, and 3% bisdemethoxycurcumin. Thimmayamma et al., Indian J. Nutr Diet 20:153-162 (1983); Bille et al., Food Chem. Toxicol. 23:967-971 (1985). The fully saturated derivative  
20 tetrahydrocurcumin is also included in the term *curcuminoid*.

Curcumin can be obtained from many sources, including for example Sigma-Aldrich, Inc. The curcumin analogs demethoxycurcumin, bisdemethoxycurcumin and tetrahydrocurcumin can also be obtained from many sources, or readily prepared from curcumin by those skilled in the art.

25 Curcumin has been used in indigenous Indian medicine for several hundred years, as a topical agent for sprains and inflammatory conditions, in addition to oral use to promote health and treat digestive and other disorders. Absorption of ingested or orally administered curcumin is known to be limited, and absorbed curcumin is rapidly metabolized. Govindarajan, CRC Critical

Rev. Food Sci Nutr. 12:199-301 (1980); Rao et al., Indian J. Med. Res. 75:574-578 (1982).

Numerous effects of the ingestion or oral administration of the curcuminoids have been reported, based on controlled research, population  
5 studies, case reports and anecdotal information. Evidence of chemopreventive activity of curcumin administered orally has led to clinical trials sponsored by the National Cancer Institute, regarding prevention of cancer. Kelloff et al., J. Cell. Biochem. Suppl. 26:1-28 (1996). Oral administration of curcumin to mice treated with skin and colon chemical carcinogens has been shown to result in a  
10 decreased incidence and size of induced tumors compared with control mice. Huang, et al., Cancer Res. 54:5841-5847 (1994); Huang et al., Carcinogenesis 16:2493-2497 (1995); Huang et al., Cancer Lett. 64:117-121; Rao et al., Cancer Res. 55:259-266 (1995); Conney et al., Adv Enzyme Regul. 31: 385-396 (1991).

Huang, et al. found that the oral administration of three curcuminoid  
15 compounds curcumin, demethoxycurcumin and bisdemethoxycurcumin were able to inhibit phorbol ester-stimulated induction of ornithine decarboxylase and promotion of mouse skin initiated with 7,12-dimethylbenzanthracene (DMBA). These compounds also inhibited phorbol ester-mediated transformation of JB6 cells. The saturated derivative tetrahydrocurcumin was less active than the  
20 unsaturated analogs in these assays. Huang et al., Carcinogenesis 16:2493-2497 (1995).

The mechanism or mechanisms of curcumin's chemopreventive activities were not previously understood, although it was recognized as an antioxidant and was known to exhibit antimutagenic activity in the Ames Salmonella test  
25 and to produce biochemical effects similar to those of the polyphenols, chemopreventive agents found in green tea. Stoner, J. Cell. Biochem. Suppl. 22:169-180 (1995). Curcumin has been demonstrated to inhibit several signal transduction pathways, including those involving protein kinase, the transcription factor NF-kB, phospholipase A2 bioactivity, arachidonic acid  
30 metabolism, antioxidant activity, and epidermal growth factor (EGF) receptor

autophosphorylation. Lu et al., Carcinogenesis 15:2363-2370 (1994); Singh et al., J. Biol. Chem. 270:24995-25000 (1995); Huang et al., Proc. Natl. Acad. Sci. U. S. A. 88:5292-5296 (1991); Korutla et al., Carcinogenesis 16:1741-1745 (1995); Rao et al., Carcinogenesis 14:2219-2225 (1993).

- 5           Because of the complexity of the factors that regulate or effect angiogenesis, and their specific variation between tissues and according to circumstances, the response to a specific agent may be different or opposite, in different tissues, under different physiological or pathological conditions and between *in vitro* and *in vivo* conditions. For example, U. S. Patent No.
- 10   5,401,504 to Das et al., discloses that oral or topical administration of turmeric to animals including humans promotes wound healing, and postulates that it acts in part through stimulation of angiogenesis, although this postulate was not experimentally verified. Administration of curcumin has been reported to inhibit smooth muscle cell proliferation *in vitro*. Huang, et al., European J.
- 15   Pharmac. 221:381-384 (1992). U. S. Patent No. 5,891,924 to Aggarwal discloses that oral administration of curcumin to animals inhibits activation of the transcription factor NF-kB, and claims its use in pathophysiological states, particularly specific conditions involving the immune system. Several biochemical actions of curcumin were studied in detail, but no single action was
- 20   reported to be responsible for these effects of curcumin. Singh et al. reported that curcumin inhibits *in vitro* proliferation of human umbilical vein endothelial cells (HUVEC) and suggested that it might have anti-angiogenic activity. However, this inhibition was independent of basic fibroblast growth factor stimulation of the proliferation of endothelial cells, and *in vivo* studies were not
- 25   reported. Singh et al., Cancer Lett. 107:109-115 (1996). Thaloor et al. disclosed inhibition by curcumin of HUVEC growth and formation of tube structures on Matrigel, in a model of capillary formation, and ascribed this inhibition to modulation of metalloproteinases of the HUVEC. Thaloor et al., Cell Growth Differ. 9:305-312 (1998).

As demonstrated by the examples, these are not the mechanism involved in inhibition of angiogenesis as described herein, and accordingly, the disorder to be treated and the dosage and means of administration are different, based on the role of curcuminoids in inhibiting bFGF.

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
2195  
2196  
2197  
2198  
2199  
2200  
2201  
2202  
2203  
2204  
2205  
2206  
2207  
2208  
2209  
2210  
2211  
2212  
2213  
2214  
2215  
2216  
2217  
2218  
2219  
2220  
2221  
2222  
2223  
2224  
2225  
2226  
2227  
2228  
2229  
2230  
2231  
2232  
2233  
2234  
2235

## B. Carriers

Pharmaceutical compositions containing the angiogenesis inhibitor are prepared based on the specific application. Application can be either topical, localized, or systemic. Any of these compositions may also include  
5   preservatives, antioxidants, antibiotics, immunosuppressants, and other biologically or pharmaceutically effective agents which do not exert a detrimental effect on the normal tissue to be treated.

Compositions for local or systemic administration will generally include an inert diluent. Solutions or suspensions used for parenteral, intradermal,  
10   subcutaneous, or topical application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as  
15   ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parental preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

### *Systemic Carriers*

20       Inhibitors can be systemically administered either parenterally or enterally. The composition can be administered by means of an infusion pump, for example, of the type used for delivering insulin or chemotherapy to specific organs or tumors, by injection, or by depo using a controlled or sustained release formulation. In a preferred systemic embodiment, drugs are administered orally,  
25   in an enteric carrier if necessary to protect the drug during passage through the stomach.

The angiogenic inhibitors can be administered systemically by injection in a carrier such as saline or phosphate buffered saline (PBS) or orally, in the case of an inhibitor such as thalidomide, in tablet or capsule form. The tablets or  
30   capsules can contain any of the following ingredients, or compounds of a similar

nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; or a glidant such as colloidal silicon dioxide. When the dosage unit form is a capsule, it can contain, in addition to material of the above type, a liquid carrier such as a fatty oil. In addition, dosage unit forms can contain various other materials which modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or other enteric agents.

#### *Local or Topical Carriers*

The angiogenic inhibitors can also be applied locally or topically, in a carrier such as saline or PBS, in an ointment or gel, in a transdermal patch or bandage, or controlled or sustained release formulation. Local administration can be by injection at the site of the injury, or by spraying topically onto the injury. The inhibitor can be absorbed into a bandage for direct application to the wound, or released from sutures or staples at the site. Incorporation of compounds into controlled or sustained release formulations is well known.

For topical application, the angiogenesis inhibitor is combined with a carrier so that an effective dosage is delivered, based on the desired activity, at the site of application. The topical composition can be applied to the skin for treatment of diseases such as psoriasis. The carrier may be in the form of an ointment, cream, gel, paste, foam, aerosol, suppository, pad or gelled stick. A topical composition for use of an ointment or gel consists of an effective amount of angiogenesis inhibitor in an ophthalmically acceptable excipient such as buffered saline, mineral oil, vegetable oils such as corn or arachis oil, petroleum jelly, Miglyol 182, alcohol-solutions, or liposomes or liposome-like products.

In a preferred form for controlled release, the composition is administered in combination with a biocompatible polymeric implant which releases the angiogenesis inhibitor over a controlled period of time at a selected site. Examples of preferred biodegradable polymeric materials include polyanhydrides, polyorthoesters, polyglycolic acid, polylactic acid, polyethylene

vinyl acetate, and copolymers and blends thereof. Examples of preferred non-biodegradable polymeric materials include ethylene vinyl acetate copolymers. These can be prepared using standard techniques as microspheres, microcapsules, tablets, disks, sheets, and fibers.

- 5           An implantable pellet is the preferred mode of local administration of these agents to tissues. The preferred concentration of curcuminoid agent delivered locally to the target tissue is greater than 10 micromolar, preferably 10-50 micromolar.

### III. Methods for Treatment

- 10           For the treatment of skin disorders, the angiogenesis inhibitors are administered topically or regionally. In a preferred embodiment, the inhibitors are administered in an ointment, salve or other pharmaceutically acceptable carrier. For treatment of certain disorders characterized by elevated levels of bFGF, the angiogenesis inhibitors, preferably curcumin or demethoxycurcumin
- 15           or another curcuminoid compound, or a combination of two or more curcuminoid compounds, is applied topically in diseases or pathologic conditions of the skin, or locally in other tissues, to treat cancer, pre-malignant conditions and other diseases and conditions in which angiogenesis occurs. The preferred means of administration is to apply the curcumin topically, for
- 20           example, as an ointment or hydrogel containing between one-half percent (0.5%) and five percent (5%) of the curcumin, or regionally, orally to treat disorders of the gastrointestinal tract or by instillation, to treat bladder or cervical cancer.

- The administration of these agents topically or locally may also be used to prevent initiation or progression of such diseases and conditions. For example, a
- 25           curcuminoid formulation may be administered topically or by instillation into a bladder if a biopsy indicated a pre-cancerous condition or into the cervix if a Pap smear was abnormal or suspicious.

- The angiogenesis inhibiting formulation is administered as required to alleviate the symptoms of the disorder. Assays can be performed to determine an
- 30           effective amount of the agent, either *in vitro* and *in vivo*. Representative assays

are described in the examples provided below. Other methods are known to those skilled in the art, and can be used to determine an effective dose of these and other agents for the treatment and prevention of diseases or other disorders as described herein.

5           The present invention will be further understood by reference to the following non-limiting examples.

As demonstrated in the examples, curcumin inhibits basic fibroblast growth factor (bFGF)-induced proliferation of endothelial cells *in vitro* and angiogenesis *in vivo*. The effect of curcumin and curcumin analogs with known  
10 differential chemopreventive activities, demethoxycurcumin, tetrahydrocurcumin, and bisdemethoxycurcumin, on *in vivo* angiogenesis was also demonstrated. Curcumin had a strong antiproliferative effect on endothelial cells, with a steep curve occurring between 5 and 10  $\mu$ M. This was true both in the presence or absence of bFGF, and this inhibition could not be overcome by  
15 the immortalizing ability of SV40 large T antigen. The corneal neovascularization assay, which measures increased vessel length and density *in vivo*, in response to a bFGF pellet placed in the normally avascular cornea, has proven useful in the confirmation and characterization of multiple angiogenesis inhibitors. The inhibition of bFGF-mediated corneal neovascularization by  
20 curcumin and its derivatives is evidence that curcumin is a direct angiogenesis inhibitor *in vivo*. This inhibition was not due to dilution of bFGF, as administration of a structurally related inactive compound, tetraphenylcyclopentadienone (TPCPD), had no effect on bFGF-induced corneal neovascularization. The lack of inhibition of TPA-mediated VEGF production  
25 further supports the role of curcumin as a direct angiogenesis inhibitor.

The following materials and methods were used in the examples.

## MATERIALS AND METHODS

### *Endothelial Proliferation Assays*

Bovine capillary endothelial cells were isolated according to the method  
30 of Folkman, et al., Proc. Nat. Acad. Sci. U. S. A. 76:5217-5221 (1979), and were

plated at a concentration of 10,000 cells/well in gelatinized 24-well dishes. The primary endothelial cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% bovine serum and grown at 37°C in 10% CO<sub>2</sub>. Twenty-four hours after plating, cells were treated with curcumin in the presence or absence of bFGF. After 72 hours of treatment, cells were counted using a Coulter counter. Cell counts for each condition were repeated in triplicate and in the presence or absence of 1ng/ml bFGF.

Similarly, MSI (ATCC CCRL 2279) endothelial cells, which are a SV40 large T antigen immortalized murine endothelial cell line, were also plated at a concentration of 10,000 cells/well in nongelatinized 24-well dishes. MSI cells do not require endothelial mitogens for growth and were cultured in DMEM supplemented with 5% fetal calf serum (FCS). Cells were counted after a 72-hour exposure to curcumin with the same method used for the bovine capillary endothelial cells.

#### *Corneal Neovascularization*

C57BL6 male mice (5-6 weeks old) were anesthetized with methoxyflurane prior to implantation of pellets and with 0.5% proparacaine. A central, intrastromal linear keratotomy was performed with a surgical blade, and a lamellar micropocket was prepared according to the method of Kenyon, et al. (1996). The pellet was advanced to the end of the pocket. Erythromycin ointment was placed on the operated eye to prevent infection. Eyes were examined by slit lamp on days 3-6 after implantation under general anesthesia. Corneal angiogenesis was assayed through two measurements.

Vessel length is the length of the vessel from the corneal limbus as it grows toward the pellet containing bFGF.

Sector size is a measurement of neovascularized area of the cornea. The cornea is viewed as a circle that can be divided into twelve sectors of 30 degrees span each, analogous to the division of a clock face into twelve hours. Thus, neovascularization of a sector corresponding to one fourth of the cornea would be recorded as a sector size measurement of three. This system of measurement,

recording sector sizes as “clock hours”, was established by Kenyon et al., Invest. Ophthalmol. 37:1625-1632 (1996).

#### *Production of VEGF mRNA in HaCaT Keratinocytes*

HaCaT keratinocytes were grown in (DMEM) (JRH) supplemented with  
5 5% FCS (Hyclone, Logan, UT) in 25cm<sup>2</sup> flasks. One hour prior to stimulation  
with 12-O-tetradecanoylphorbol-13-acetate (TPA), cells were switched to  
serumless media supplemented with 10µM curcumin or an equal quantity of  
ethanol (final concentration 0.1%). TPA was added to a final concentration of  
5ng/ml and cells were incubated for three hours at 37°C and harvested, and their  
10 RNA was extracted with guanidinium thiocyanate/phenol.

#### *Phase II Enzyme Induction*

The ability of curcumin derivatives to induce phase II activities was  
measured by assaying quinone reductase [NAD(P)H:(quinone-acceptor)  
oxidoreductase, EC1.6.99.2] in murine Hepac1c7 cells. Serial dilutions of  
15 curcumin, curcumin derivatives, and tetraphenylcyclopentadienone (TPCPD)  
were added, and the concentration of compound required to double the specific  
activity (CD) was calculated according to the method of Prochaska, et al., Proc.  
Natl. Acad. Sci. U. S. A. 89:2394-2398 (1992).

#### *Materials*

20 Curcumin, TPA and TPCPD were obtained from Sigma-Aldrich, Inc.  
Curcumin analogs (bisdemethoxycurcumin, demethoxycurcumin and  
tetrahydrocurcumin) were provided by Dr. A. R. Conney of Rutgers-The State  
University of New Jersey.

C57BL6 mice were obtained from Charles River Laboratories. The MS1  
25 transformed cells were developed by Dr. J. L. Arbiser and deposited with the  
ATCC (ATCC CCRI 2279).

#### *Implant Pellets*

Pellets were prepared according to a modification of the method of  
Kenyon, et al. Invest. Ophthalmol. Vis. Sci. 37:1625-1632 (1996). An aqueous  
30 solution of 18 mcg of basic fibroblast growth factor (Scios Nova, Mountain

View, California) was evaporated to dryness under reduced pressure in the presence of 10 mg of sucralfate (Bukh Meditec, Vaerloose, Denmark) Ten microliters of 12% hydron and 10 mg of curcumin or curcumin analog were then added, and the homogenous mixture was deposited onto a sterile 15 x 15 mm 3-  
5 300/50 Nylon mesh (Tetko, Lancaster, NY) and air dried. Once the mixture was dry, the mesh was manually dissociated to yield 225 pellets. Each pellet contained 80 ng of bFGF and 44 µg of curcumin or curcumin analog. Pellets containing hydron in the absence of bFGF do not cause neovascularization, so pellets prepared in the absence of bFGF were not used in this study. The  
10 approximate pore size was 0.4 x 0.4mm. Both sides of the mesh were covered with a thin layer of hydron.

#### *Isotopically Labelled Antisense Riboprobe*

A plasmid containing the coding region of human vascular endothelial growth factor (VEGF) 121 was obtained from H. Welch (University of Freiburg,  
15 Germany), and used to generate P<sup>32</sup>-labeled antisense riboprobe as per manufacturers protocols (Ambion, Austin, TX). RNase protection assays were performed according to the method of Hod, Biotechniques 13:852-853 (1992). Protected fragments were separated on gels of 5% acrylamide, 8 M urea, 1 x Tris-borate buffer, and quantified with a phosphorimager (Molecular Dynamics,  
20 Sunnyvale, CA). An 18S riboprobe was included in each sample to normalize for variations in loading and recovery of RNA.

#### *Measurement and Analysis*

Significant differences between two groups were determined using an unpaired, two-tailed Student's t-test. Results are expressed as the mean plus or  
25 minus the standard error of the mean.

**Example 1: Curcumin inhibition of endothelial cell proliferation is dependent on curcumin dose and the presence or absence of basic fibroblast growth.**

Endothelial cells were stimulated to proliferate in the presence of 1ng/ml bFGF. Curcumin was added in concentrations ranging from 0.5 to 10  $\mu$ M to primary endothelial cells.

Figures 1A-C describe the effect of curcumin on endothelial cell proliferation in the absence of basic fibroblast growth factor (bFGF; Figure 1A), in the presence of bFGF (Figure 1B) and in the absence of bFGF, where the endothelial cells have been transformed (Figure 1C). A steep decrease in cell number was seen at 10 $\mu$ M. No evidence of cytotoxicity was observed, and the number of cells at the end of treatment was not significantly less than the number cells originally plated. This decrease in proliferation due to curcumin concentration of 10 $\mu$ M was observed in both the presence or absence of bFGF.

In addition, curcumin was able to inhibit the growth of endothelial cells immortalized by SV40 large T antigen, with a similar dose response as seen with primary endothelial cells.

**Example 2: Curcumin inhibition of corneal neovascularization is dependent on the presence of basic fibroblast growth factor.**

The ability of curcumin to inhibit bFGF-induced corneal neovascularization *in vivo* was measured. Pellets were prepared containing 80 ng of bFGF and curcumin, or a control aromatic ketone, tetraphenylcyclopentadienone (TPCPD). TCPD was added to rule out the possibility that the inhibition of neovascularization due to curcumin was not secondary to dilution. Neovascularization was assessed by slit lamp at 5 days after implantation, and the corneas were photographed.

Figures 2A-2B describe the effect of curcumin on the extent of bFGF-stimulated neovascularization in the mouse cornea (Figure 2A), in relation to bFGF-stimulated neovascularization in the absence of curcumin (Figure 2B). There was no difference in neovascularization in mice containing bFGF pellets

in the presence or absence of TPCPD. Both the vessel length and sector sizes were significantly reduced in the presence of curcumin.

**Example 3: Curcumin and other curcumin analog inhibition of corneal neovascularization in the presence of basic fibroblast growth factor is dependent on the dose and structure of the curcuminoid.**

Three curcumin analogs were assayed for their ability to inhibit bFGF-induced corneal neovascularization as described above.

Figures 3A and 3B describe the effect of curcumin and other curcuminoids, tetrahydrocurcumin, bisdemethoxycurcumin, and demethoxycurcumin, on corneal neovascularization, as measured by vessel length (Fig. 3A) and by sector size (Fig. 3B). All analogs showed inhibitory activity, with demethoxycurcumin showing the greatest activity on both sector size and vessel length, tetrahydrocurcumin having the least effect on sector size, and bisdemethoxycurcumin having the least effect on vessel length. All of the curcumin analogs showed significant inhibition of bFGF-mediated neovascularization compared with control pellets.

**Example 4: Curcumin does not inhibit vascular endothelial growth factor mRNA production in transformed keratinocytes.**

HaCaT cells are derived from spontaneously transformed human keratinocytes. In order to determine whether curcumin could inhibit production of angiogenesis factors by relevant tumor cells as well as directly inhibit endothelial function; HaCaT cells were treated with tetradecanoylphorbol ester (TPA) in the presence or absence of curcumin and expression of VEGF mRNA was measured.

TPA caused a 2.5-fold increase in VEGF mRNA. This increase was not inhibited by curcumin. Thus the primary antiangiogenic effect of curcumin is directly on endothelium, rather than inhibition of production of VEGF, an important angiogenic factor.

**Example 5: Inhibition of corneal neovascularization by curcumin and other curcuminoids does not correlate with the induction of Phase II enzymes by curcumin and other curcuminoids.**

Several plant-derived compounds with anticancer and chemopreventive activities also show the ability to induce phase II detoxifying enzymes, including quinone reductase. To determine whether the antiangiogenic activities of curcumin derivatives correlated with the ability to induce quinone reductase activity, the concentration needed to double the specific activity value (CD) was determined.

10 All of the curcumin analogs studied except tetrahydrocurcumin had approximately equal potencies in induction of phase II enzymes, a measure of detoxification activity, whereas the fully saturated tetrahydrocurcumin has little ability to induce phase II enzymes. Tetrahydrocurcumin, the curcumin derivative with the least antitumor activity, caused a 1.6-fold induction of

15 quinone reductase activity at the highest concentration tested, 25  $\mu$ M. However, TPCPD, which is an unsaturated aromatic ketone with no anti-angiogenic activity, had a CD value of 4.8 $\mu$ M. The results are shown in Table 1. Thus, antiangiogenic activity does not correlate with phase II activity. This finding is evidence that the two processes are not based on similar mechanisms.

20 Modifications and variations of the methods and compositions described herein will be obvious to those skilled in the art and are intended to come within the scope of the appended claims.

**Table 1: Actual and Relative Effects of Curcuminoids and TPCPD**  
**On Phase II Enzyme Induction and Angiogenesis**

**PHASE II**

<u>COMPOUND</u>	<u>INDUCTION</u>		<u>ANTI-ANGIOGENIC EFFECT</u>			
	CD <sup>1</sup>	Rank <sup>2</sup>	Sector Size <sup>3</sup> ( $\mu$ M)	Rank <sup>2</sup>	Vessel Length (mm.)	Rank <sup>2</sup>
Tetrahydro- curcumin	>25	1	2.43	2	0.74	3
Bisdemethoxy- curcumin	11.0	2	1.7	3	0.88	2
Demethoxy- curcumin	9.0	3	0.71	5	0.26	5
Curcumin	7.3	4	1.17	4	0.59	4
TPCPD	4.8	5	3.72	1	1.16	1

Notes:

1. Concentration to double the measured specific activity; negatively correlated with effectiveness
2. Rank: Relative effectiveness in Phase II enzyme induction or in antiangiogenic effect (reduction of sector size or vessel length)
3. Sector size expressed in units of 1/12 of a circle, or 30 degrees (equivalent to "clock hours")